Inflammatory Bowel Disease

Early treatment with infliximab plus an immunomodulator resulted in more frequent steroid-free and surgery-free remission at 1 year compared with conventional therapy among patients with newly diagnosed Crohn’s disease, researchers reported.

In a Healio video exclusive, Sneha Dave, recaps a roundtable series presented by the Crohn’s and Colitis Young Adults Network, which encourages young adults with inflammatory bowel disease to discuss gaps and opportunities in research.

In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses data he presented at the GUILD Conference, which show patients with inflammatory bowel disease are at increased risk for cardiovascular events, likely driven by inflammation.

A 12-point plan from the AGA proposed ways in which collaboration between the health care community, insurers, pharmaceutical companies and legislators can improve “fixable problems” affecting patients with inflammatory bowel disease.

Screening patients with psoriasis, uveitis or inflammatory bowel disease for spondyloarthritis could improve early diagnosis, but no existing screening tools are generalizable to all who are at risk, according to a scoping review.

In a Healio video exclusive, Gil Y. Melmed, MD, MS, highlights certain therapies that should be avoided or included in the management of patients with extraintestinal manifestations of inflammatory bowel disease.

In a Healio video exclusive, Gil Y. Melmed, MD, MS, outlines seven principles supported by literature that “help to frame” how providers should address routine preventive vaccination for patients with inflammatory bowel disease.

Treatment with Stelara for inflammatory bowel disease did not increase the risk for adverse maternal or fetal pregnancy outcomes, and infants exposed in utero reached developmental milestones in the first year of life, data showed.

In this Healio video exclusive, Michael V. Chiorean, MD, explains that physicians can safely and “with confidence” switch patients with inflammatory bowel disease from an originator biologic to a biosimilar at any point during treatment.

Anita Afzali, MD, MPH, FACG, executive vice chair of medicine and professor of clinical medicine at University of Cincinnati College of Medicine,  spoke with Healio about ulcerative colitis.